Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

Research output: Contribution to journalArticle

Abstract

Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.

Details

Authors
  • Andreas Hillarp
  • Kerstin M Gustafsson
  • Lars Faxälv
  • Karin Strandberg
  • Fariba Baghaei
  • Inger Fagerberg Blixter
  • Maria Berndtsson
  • Tomas L Lindahl
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cardiac and Cardiovascular Systems
Original languageEnglish
Pages (from-to)1545-1553
JournalJournal of Thrombosis and Haemostasis
Volume12
Issue number9
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes